References
- Petersen P, Bousen G, Gotfredsen J, Andersen E, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet 1989; 8631: 175–9
- Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of longterm oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499–503.
- Nilsson GH, Bjorholt I, Johnsson H. Anticoagulant treatment in primary health care in Sweden – prevalence, incidence and treatment diagnosis: A retrospective study on electronic patient records in a registered population. BMC Fam Pract 2003; 4: 3
- Hallinen T, Martikainen JA, Soini EJ, Souminen L, Aronkyto T. Direct costs of warfarin treatment among patients with atrial fibrillation in a Finnish health care setting. Curr Med Res Opin 2006; 22: 683–92
- Fanikos J, Grasso-Correnti N, Shah R, Kucher N, Goldhaber SZ. Major bleeding complications in specialized anticoagulation service. Am J Cardiol 2005; 96: 595–8
- Landefeld C, Beyth R. Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention. Am J Med 1993; 95: 315–28
- Fang MC, Go AS, Hylek EM, Chang Y, Henault LE, Jensvold NG, Singer DE. Age and the risk of warfarin-associated hemorrhage: The anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc 2006; 54: 1231–6
- Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423–8
- Torn M, Bollen WL, van der Meer FJ, van der Wall EE, Rosendaal FR. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med 2005; 165: 1527–32
- Beyth R, Landefeld C. Anticoagulants in older patients. Drugs & Aging 1995; 6: 45–54
- Berwaerts J, Webster J. Analysis of risk factors involved in oral-anticoagulant-related intracranial haemorrhages. Q J Med 2000; 93: 513–21
- Lighttowlers S, McGuire A. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke. Stroke 1998; 29: 1827–32
- Jansson J, Westman G, Boman K, Nilsson T, Norberg B. Oral anticoagulant treatment in a medical care district: A descriptive study. Scand J Prim Health Care 1995; 13: 268–74
- Kalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ 2000; 320: 1236–9
- Perrero PP, Willoughby DF, Eggert JA, Counts SH. Warfarin therapy in older adults: Managing treatment in the primary care setting. J Gerontol Nurs 2004; 30: 44–54
- White R, McKittrick T, Takakuwa J, Callahan C, McDonell M, Fihn S. Management and prognosis of life-threatening bleeding during warfarin therapy. Arch Intern Med 1996; 156: 1197–201
- Johnsson H. Anticoagulant therapy can be safer: An active follow-up and written care programs reduce the number of complications [in Swedish]. Läkartidningen 1999; 96: 3388–90
- Bond C, Raehl C. Pharmacist-provided anticoagulation management in United States hospitals: Death rates, length of stay, Medicare charges, bleeding complications, and transfusions. Pharmacotherapy 2004; 24: 953–63
- Wandell PE. Anticoagulant treatment of patients in Swedish primary health care: Safety aspects. Eur J Clin Pharmacol 2001; 57: 61–4
- Panneerselvam S, Baglin C, Lefort W, Baglin T. Analysis of risk factors for over anti-coagulation in patients receiving long-term Warfarin. Br J Hematol 1998; 103: 422–4
- Kucher N, Connolly S, Beckman J, et al. International normalized ratio increase before warfarin-associated hemorrhage: Brief and subtle. Arch Intern Med 2004; 164: 2176–9